文献速递肝病消化道肿瘤与早癌

非增强MRI检测肝细胞癌:系统综述与Meta分析

Noncontrast MRI for Hepatocellular Carcinoma Detection: A Systematic Review and Meta-analysis - A Potential Surveillance Tool?
PubMed 文献 · Clin Gastroenterol Hepatol · 2021-03-02

多序列非增强MRI的汇总每患者敏感度为86.8%、特异度为90.3%,阴性似然比为0.17;DWI-only MRI敏感度为79.2%、特异度为96.5%。结论认为非增强MRI具有中等阴性似然比和高特异度,敏感度可接受,但需前瞻性试验验证其用于HCC监测的价值。

要点

  • 多序列非增强MRI检测HCC的汇总敏感度86.8%、特异度90.3%。
  • DWI-only MRI特异度达96.5%,但敏感度较低(79.2%)。
  • 肝硬化患者及<2 cm病灶中非增强MRI仍保持可接受敏感度。

核心结论

  • 非增强MRI检测HCC具有中等阴性似然比和高特异度,敏感度可接受,甚至适用于肝硬化及<2 cm病灶患者。
  • 需前瞻性试验验证非增强MRI能否用于HCC监测。

研究设计与样本

  • 系统综述与Meta分析,检索至2020年5月,纳入评估非增强MRI(多序列或DWI-only)在高危患者中检测HCC诊断性能的研究。
  • 采用随机效应模型汇总敏感度、特异度、阳性似然比和阴性似然比,并按肝硬化和病灶大小进行亚组分析。

主要发现

  • 多序列非增强MRI(T2+DWI±T1序列)每患者汇总敏感度86.8%(95%CI:83.9-89.4%),特异度90.3%(95%CI:87.3-92.7%),阴性似然比0.17(95%CI:0.14-0.20)。
  • DWI-only MRI汇总敏感度79.2%(95%CI:71.8-85.4%),特异度96.5%(95%CI:94.3-98.1%),阴性似然比0.24(95%CI:1.62-0.34)。
  • 肝硬化患者中,非增强MRI汇总每患者敏感度87.3%(95%CI:82.7-91.0%),特异度81.6%(95%CI:75.3-86.8%);DWI-MRI汇总敏感度71.4%(95%CI:60.5-80.8%),特异度97.1%(95%CI:91.9-99.4%)。
  • 病灶<2 cm时汇总每病灶敏感度77.1%(95%CI:73.8-80.2%);病灶>2 cm时汇总每病灶敏感度88.5%(95%CI:85.0-91.5%)。

临床怎么用

  • 非增强MRI可作为高危患者HCC检测的潜在工具,尤其适用于无法使用增强造影剂的患者。
  • 高特异度和中等阴性似然比提示非增强MRI阴性时患HCC可能性较低,但需结合临床情境。
  • 目前证据尚不足以推荐非增强MRI常规用于HCC监测,需前瞻性试验进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: This meta-analysis investigates the diagnostic performance of non-contrast magnetic resonance imaging (MRI) for the detection of hepatocellular carcinoma (HCC). METHODS: A systematic review was performed to May 2020 for studies which examined the diagnostic performance of non-contrast MRI (multi-sequence or diffusion-weighted imaging (DWI)- alone) for HCC detection in high risk patients. The primary outcome was accuracy for the detection of HCC. Random effects models were used to pool outcomes for sensitivity, specificity, positive likelihood ratio (LR) and negative LR. Subgroup analyses for cirrhosis and size of the lesion were performed. RESULTS: Twenty-two studies were included involving 1685 patients for per-patient analysis and 2128 lesions for per-lesion analysis. Multi-sequence non-contrast MRI (NC-MRI) using T2+DWI±T1 sequences had a pooled per-patient sensitivity of 86.8% (95%CI:83.9-89.4%), specificity of 90.3% (95%CI:87.3-92.7%), and negative LR of 0.17 (95%CI:0.14-0.20). DWI-only MRI (DW-MRI) had a pooled sensitivity of 79.2% (95%CI:71.8-85.4%), specificity of 96.5% (95%CI:94.3-98.1%) and negative LR of 0.24 (95%CI:1.62-0.34). In patients with cirrhosis, NC-MRI had a pooled per-patient sensitivity of 87.3% (95%CI:82.7-91.0%) and specificity of 81.6% (95%CI:75.3-86.8%), whilst DWI-MRI had a pooled sensitivity of 71.4% (95%CI:60.5-80.8%) and specificity of 97.1% (95%CI:91.9-99.4%). For lesions <2 cm, the pooled per-lesion sensitivity was 77.1% (95%CI:73.8-80.2%). For lesions >2 cm, pooled per-lesion sensitivity was 88.5% (95%CI:85.0-91.5%). CONCLUSION: Non-contrast MRI has a moderate negative LR and high specificity with acceptable sensitivity for the detection of HCC, even in patients with cirrhosis and with lesions <2 cm. Prospective trials to validate if non-contrast MRI can be used for HCC surveillance is warranted.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Chan MV, Huo YR, Trieu N, et al. Noncontrast MRI for Hepatocellular Carcinoma Detection: A Systematic Review and Meta-analysis - A Potential Surveillance Tool? Clin Gastroenterol Hepatol. 2021. PMID: 33662596. doi:10.1016/j.cgh.2021.02.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。